secwatch.observer — SEC 8-K summary
======================================

Issuer:     908 Devices Inc. (MASS)
CIK:        0001555279
Form:       8-K
Filed at:   2022-03-07T23:59:59+00:00
Accession:  0001104659-22-031039
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

908 Devices Q4 rev $15.8M (+177% YoY); net loss $3.5M; FY22 guide $52-55M
-------------------------------------------------------------------------

- Full-year 2021 revenue $42.2M (+57% YoY); net loss $22.2M ($0.79 loss per share).
- Q4 gross margin improved to 58% from 49%; installed base expanded to 1,935 devices.
- Cash $224M at year-end; debt outstanding $15M.
- FY 2022 revenue outlook $52M-$55M, representing 23%-30% growth over FY 2021.
- Commercial traction with all top 20 biopharma; Tony Hunt (Repligen CEO) added to board.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1555279/000110465922031039/0001104659-22-031039-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1555279/000110465922031039/tm228482d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-031039

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer